Gregor Diagnostics

gregordiagnostics.com →

-62%

est. 2Y upside i

Series A

Rank

#1535

Sector

Molecular Diagnostics

Est. Liquidity

~6Y

Data Quality

Data: Medium

Gregor Diagnostics presents a moderate upside opportunity with a high level of risk for a job seeker.

Last updated: March 10, 2026

Bull (17%)+400%

The groundbreaking prostate cancer screening test successfully navigates large FDA Pivotal Trials, achieves rapid regulatory approval, and gains significant market adoption due to its superior early detection and differentiation capabilities. This leads to a successful acquisition by a major diagnostics player at a valuation of $175M, representing a 5x return on the estimated current valuation.

Base (48%)+50%

Gregor Diagnostics successfully completes clinical trials and secures regulatory approval, but market penetration is slower than anticipated due to incumbent competition and payer adoption challenges. The company achieves moderate growth, leading to an eventual acquisition at a valuation of $52.5M, a 1.5x return on the estimated current valuation.

Bear (35%)-80%

The company faces significant delays or setbacks in its large FDA Pivotal Trial, or a major incumbent like Exact Sciences develops a competing technology that erodes Gregor's market opportunity. This results in a down round or a low-value acquisition at $7M, wiping out most common stock value given the substantial liquidation preferences.

Est. time to liquidity~6.0 years

Preference Stack Risk

severe

Investors hold $14.6M in liquidation preferences ahead of common stock, representing 41.7% of the estimated $35M valuation.

Dilution Risk

high

As a clinical-stage company with very high capital intensity, multiple future funding rounds are anticipated, leading to significant dilution.

Secondary Liquidity

none

There is no publicly available information indicating an active secondary market or tender offers for Gregor Diagnostics' shares.

Questions to Ask at the Interview

Strategic questions based on Gregor Diagnostics's data — designed to show you've done your homework.

  • 1

    “Given the 'very high' capital intensity and the need for a large FDA Pivotal Trial, how is Gregor Diagnostics planning to manage its burn rate and secure the necessary funding without excessive dilution in upcoming rounds?”

  • 2

    “The company holds an exclusive license for proprietary biomarkers. How does Gregor Diagnostics plan to leverage this strong competitive moat to defend against potential incumbent threats from companies like Exact Sciences as the product approaches commercialization?”

  • 3

    “With the current estimated valuation and total funding, there's a significant liquidation preference. How does the company communicate the potential equity value and liquidity timeline to employees, especially given the long path to market for a clinical-stage diagnostic test?”

Community

Valuation Sentiment

Our model estimates -62% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.